SCHEMBL23609529

SCHEMBL23609529

CCCC(C)CCn1cncn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.45
EGLN3 Q9H6Z9 1/20 0.42
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 2/20 0.35
KDM4E B2RXH2 3/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
USP2 O75604 1/20 0.33
HSD17B10 Q99714 1/20 0.33
UGT1A4 P22310 1/20 0.33
PDE4D Q08499 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25022444 0.83 TSHR (0.37) CYP19A1EGLN3TSHRPOLBMEN1
SCHEMBL13886384 0.80 CYP19A1 (0.50) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2
SCHEMBL4550582 0.79 EGLN3 (0.50) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2
SCHEMBL11959513 0.78 EGLN3 (0.42) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2
SCHEMBL45842 0.78
SCHEMBL11202609 0.76 EGLN3 (0.44) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2
SCHEMBL23875630 0.76 TLR8 (0.39) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2
SCHEMBL26045021 0.75 CYP19A1 (0.43) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2
SCHEMBL13741693 0.75 EGLN3 (0.46) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2
SCHEMBL10515720 0.74 CYP19A1 (0.49) CYP19A1EGLN3ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11766449-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-09-26 US disclosed
US-20230226096-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-07-20 US disclosed
US-11679120-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-06-20 US disclosed
US-20230058784-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-02-23 US disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226096-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RTCB, HNRNPA1, HNRNPAB CYP19A1 2822/4885EGLN3 2566/4885ALDH1A1 4484/4885
US-20230058784-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RTCB, RNGTT, HNRNPAB CYP19A1 3057/4885EGLN3 3028/4885ALDH1A1 4532/4885
US-11679120-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB CYP19A1 2822/4885EGLN3 2566/4885ALDH1A1 4484/4885
US-11766449-B2 Circular RNA compositions and methods RTCB, RNGTT, HNRNPAB CYP19A1 3057/4885EGLN3 3028/4885ALDH1A1 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.